Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
As part of its steps to enhance patient engagement, on June 23 2020, the US Food and Drug Administration (FDA) launched Project Patient Voice, a publicly-available website that shares information about patient-reported outcomes (PROs) from cancer clinical trials for marketed treatments. 6 August 2020
Pharmaceutical
The Indian government is drawing up an exhaustive research and development (R&D) policy for the pharmaceutical sector as it aims to propel India’s drug industry to be on par with countries like the USA and Europe. 6 August 2020
Biotechnology
Spinal muscular atrophy (SMA) is a hereditary, progressive neurodegenerative disorder. It is characterized by motor neuron degeneration in the spinal cord, leading to skeletal muscle atrophy, weakness and profound physical disability. SMA is the leading genetic cause of infant mortality, affecting around 1 in 6,000 to 1 in 10,000 live births worldwide each year.1 3 August 2020
Pharmaceutical
The High Court has handed down its second judgment in Merck KGaA v Merck Sharp & Dohme, the long-running dispute between two pharmaceutical companies regarding use of the MERCK trade mark. 3 August 2020
Pharmaceutical
Developments in artificial intelligence (AI) and machine learning (ML) are playing an increasingly influential role in the biotech space, driving the formation of new partnerships ,between the tech and healthcare industries. 3 August 2020
Pharmaceutical
Global drugmakers operating in Russia will be able to label their drugs directly at customs warehouses in Russia, which will allow them to save on costs and facilitate imports of many of foreign drugs to the Russian market. 30 July 2020
Generics
As the scheme to make India self-reliant in bulk drug supply gets underway, the Department of Pharmaceuticals (DoP) is to shift its focus to encourage research and development of novel drugs in the country. While a new policy is in the works, the government has announced a $1.33 billion booster for ramping up domestic production of raw materials for producing drugs, reports The Pharma Letter’s India correspondent. 28 July 2020
Pharmaceutical
Catherine Penny, partner, and Elizabeth Butler, associate, Stevens and Bolton LLP, provide an Expert View on an important issue thrown up by the pandemic. 24 July 2020
Biotechnology
Chinese publication Science and Technology Daily has analyzed the progress of the AstraZeneca and University of Oxford coronavirus vaccine alongside a competitor from China. 24 July 2020
Pharmaceutical
A collaborative framework in which national and foreign actors converge allows the people of Uruguay access to a wide range of medicines, and the resilience of this structure has been shown during the COVID-19 pandemic, writes The Pharma Letter's Latin American correspondent. 23 July 2020
Pharmaceutical
The Russian government plans to require global drugmakers operating in the local market to spend up to 20% of revenue on the R&D activities within Russia, otherwise threating to annul patent protection of their drugs in the local market, according to recent statements made by some senior government officials. 21 July 2020
Pharmaceutical
The total value of M&A deals in the pharmaceutical and biotech sector was down by more than 88.5% in the first half of 2020, compared to the same period in 2019. 17 July 2020
Pharmaceutical
While vaccine developers including Moderna Therapeutics and AstraZeneca have reported promising results from their COVID-19 programs, the world urgently needs better options for the large number of people being hospitalized with the disease. 17 July 2020
Pharmaceutical
The coronavirus pandemic has put many things on hold as many parts of the world are still under lockdown. Even in countries where things were beginning to open up, like in the U.S., there is an uptick in cases and public health officials are concerned about a second wave. 14 July 2020
Generics
Amid the ever-tightening competition in the Russian pharmaceutical market, global drugmakers continue to cut their local range as part of efforts for optimization of local business, reports The Pharma Letter’s local correspondent. 14 July 2020
Biosimilars
Although complexities inherent in biological drug manufacturing are creating barriers for further expansion of the biosimilars market, imminent patent expiries of key biologics are set to create new opportunities for biosimilar manufacturers in India. The Indian government is also pushing the domestic industry to capitalize on the fact that COVID-19 provides a larger opportunity to shape the biosimilar landscape, reports The Pharma Letter’s India correspondent. 13 July 2020
Pharmaceutical
Gary Ashford, partner and chartered tax advisor at law firm Harbottle and Lewis, looks at tax issues around clinical research in the UK in an Expert View piece. 9 July 2020
Pharmaceutical
The global remote patient monitoring (RPM) market is advancing at a significant rate across the entire healthcare industry, notes Dr Nicola Davies in her exclusive column for the Pharma Letter. This has most recently been driven by the COVID-19 pandemic1 and the US Food and Drug Administration’s guidance for the expanded use of certain approved RPM devices during this period.2 8 July 2020
Pharmaceutical
The Russian government expects 20% growth of the domestic drug production this year, according to recent statements made by Denis Manturov, head of the Russian Ministry of Industry and Trade, a stage agency, which is responsible for the development of pharmaceutical industry in the Russian government. 7 July 2020
Pharmaceutical
An Expert View from Jonathan Roses, counsel, Wolf, Greenfield & Sacks, and Toby Simpson, partner, Hoffmann Eitle, exploring legal differences between the two major jurisdictions of the USA and Europe that life sciences companies should be aware of. 3 July 2020
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze